| Filed On | Filing |
|---|---|
| 16 Nov 2026 | SCHEDULE 13G/A |
| 04 Nov 2026 | 10-Q |
| 04 Nov 2026 |
8-K: Results of Operations and Financial Condition
Positive topline results from Phase 2 trial of RAP-219 in bipolar mania; initiation of two Phase 3 trials in bipolar mania expected in 2H 2027 |
| 03 Nov 2026 |
Form 4: Third Rock Ventures V, L.p., Director and 5 others
Received 1,428,571 shares as a grant or award ($30M) |
| 30 Oct 2026 |
Form 4: Healy James, Director
Bought 969,480 shares ($20.4M) |
| 30 Oct 2026 |
8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition +2 more
This Cross-Reference Table does not constitute part of the Indenture and shall not have any bearing on the interpretation of any of its terms or provisions. |
| 30 Oct 2026 | 424B5 |
| 30 Oct 2026 | 424B5 |
| 29 Oct 2026 | 305B2 |
| 28 Oct 2026 | FWP |
| 28 Oct 2026 | FWP |
| 28 Oct 2026 | FWP |
| 28 Oct 2026 | FWP |
| 27 Oct 2026 | 424B5 |
| 27 Oct 2026 | 424B5 |
| 23 Oct 2026 |
Form 4: Ceesay Abraham, Director
Sold 2,210 shares ($64.4K) |
| 23 Oct 2026 |
Form 4: Sanchez Ramiro, Director
Bought 3,600 shares ($98.5K) |
| 22 Oct 2026 |
Form 4: Silva Paul M, Director
Bought 3,680 shares ($99.6K) |
| 22 Oct 2026 |
Form 4: Young Wendy B., Director
Bought 3,789 shares ($100K) |
| 22 Oct 2026 |
Form 4: Paul Steven M, Director
Bought 35,714 shares ($974K) |
Loading...